Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3213308 | 0.89 | DRD2 (0.49) | SMN1; SMN2LMNAHTTMAPK1ALDH1A1 | |
| SCHEMBL14590807 | 0.86 | LMNA (0.46) | SMN1; SMN2LMNAHTTMAPK1ALDH1A1 | |
| SCHEMBL908271 | 0.84 | ABL1 (0.59) | SMN1; SMN2LMNAHTTMAPK1ALDH1A1 | |
| SCHEMBL1008089 | 0.83 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1GAADRD2ABL1 | |
| SCHEMBL31594790 | 0.83 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1GAADRD2ABL1 | |
| SCHEMBL3229106 | 0.82 | ALDH1A1 (0.48) | ALDH1A1GAADRD2ABL1RIN1 | |
| SCHEMBL2002022 | 0.82 | ALDH1A1 (0.67) | LMNAMAPK1ALDH1A1GAANFKB1 | |
| SCHEMBL30038050 | 0.82 | ALDH1A1 (0.67) | LMNAMAPK1ALDH1A1GAANFKB1 | |
| SCHEMBL2561574 | 0.81 | GAA (0.66) | SMN1; SMN2LMNAHTTMAPK1ALDH1A1 | |
| SCHEMBL25729047 | 0.81 | PPARG (0.51) | SMN1; SMN2LMNAHTTMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608633-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS I FOR TREATING HIV MEDIATED DISEASES | HOFFMANN LA ROCHE (CH) | 2016-04-20 | — | — | EP | disclosed |
| US-8329755-B2 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329755-B2 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC (US) | 2012-12-11 | — | — | US | disclosed |
| US-20100041648-A1 | METHODS FOR TREATING RETROVIRAL INFECTIONS | DUNN JAMES PATRICK | 2010-02-18 | — | — | US | disclosed |
| US-20100041648-A1 | METHODS FOR TREATING RETROVIRAL INFECTIONS | DUNN JAMES PATRICK | 2010-02-18 | — | — | US | disclosed |
| CN-100588650-C | Non-nucleoside reverse transcriptase inhibitors I for the treatment of HIV mediated diseases | HOFFMANN LA ROCHE | 2010-02-10 | — | — | CN | disclosed |
| US-7625949-B2 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625949-B2 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1742908-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-7348345-B2 | Nonnucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2008-03-25 | — | — | US | disclosed |
| CN-1759104-A | Non-nucleoside reverse transcriptase inhibitors I for the treatment of HIV mediated diseases | HOFFMANN LA ROCHE (CH) | 2006-04-12 | — | — | CN | disclosed |
| EP-1608633-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS I FOR TREATING HIV MEDIATED DISEASES | F. Hoffmann-La Roche AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| EP-1608629-A1 | BENZYL-PYRIDAZINONS AS REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| WO-2005102989-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-03 | — | — | WO | disclosed |
| US-20050239881-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2005-10-27 | — | — | US | disclosed |
| US-20050239880-A1 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC | 2005-10-27 | — | — | US | disclosed |
| US-20040198736-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2004-10-07 | — | — | US | disclosed |
| WO-2004085411-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS I FOR TREATING HIV MEDIATED DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004085406-A1 | BENZYL-PYRIDAZINONS AS REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | disclosed |
| US-20040192704-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041648-A1 | METHODS FOR TREATING RETROVIRAL INFECTIONS | CCR5, CXCR4, CCR1 | SMN1; SMN2 527/4885LMNA 1961/4885HTT 1980/4885 |
| US-20050239880-A1 | Methods for treating retroviral infections | CCR5, CD38, CD4 | SMN1; SMN2 1944/4885LMNA 2586/4885HTT 2671/4885 |
| US-20040192704-A1 | Non-nucleoside reverse transcriptase inhibitors | POLR1A, POLA1, REV1 | SMN1; SMN2 1062/4885LMNA 1842/4885HTT 2589/4885 |
| US-20040198736-A1 | Non-nucleoside reverse transcriptase inhibitors | POLR1A, POLR2A, POLR2E | SMN1; SMN2 1790/4885LMNA 1382/4885HTT 3958/4885 |
| US-20050239881-A1 | Non-nucleoside reverse transcriptase inhibitors | RPP30, PNP, RTF1 | SMN1; SMN2 2230/4885LMNA 1159/4885HTT 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.